Literature DB >> 20574170

Ocular adnexal lymphomas: a review.

Penelope A McKelvie1.   

Abstract

Ocular adnexal lymphomas comprise 1% to 2% of all non-Hodgkin lymphomas and about 8% of extranodal lymphomas. They are a heterogeneous group of malignancies, the majority of which are primary extranodal lymphoma with most (up to 80%) of the marginal zone of mucosa associated lymphoid tissue type (MALT lymphoma). This review will encompass the incidence, histology, immunophenotyping, recent advances in molecular and cytogenetics, clinical features including outcome, and prognostic factors. The association with Chlamydia psittaci and the very recently recognized occurrence in the context of IgG4-related sclerosing disease will be discussed. Finally, traditional (surgery, radiotherapy, chemotherapy) and newer forms of therapy (immunotherapy and radioimmunotherapy) will be reviewed.

Entities:  

Mesh:

Year:  2010        PMID: 20574170     DOI: 10.1097/PAP.0b013e3181e4abdb

Source DB:  PubMed          Journal:  Adv Anat Pathol        ISSN: 1072-4109            Impact factor:   3.875


  18 in total

1.  Immunophenotypic profiles for distinguishing orbital mucosa-associated lymphoid tissue lymphoma from benign lymphoproliferative tumors.

Authors:  Shunichiro Ueda; Yoshihiko Usui; Takeshi Nagai; Daniel Diaz-Aguilar; Toshitaka Nagao; Hiroshi Goto
Journal:  Jpn J Ophthalmol       Date:  2017-04-18       Impact factor: 2.447

2.  A prevalence study of IgG4-related ophthalmic disease in Japan.

Authors: 
Journal:  Jpn J Ophthalmol       Date:  2013-08-07       Impact factor: 2.447

3.  Orbital lymphoma: imaging features and differential diagnosis.

Authors:  Gema Priego; Carles Majos; Fina Climent; Amadeo Muntane
Journal:  Insights Imaging       Date:  2012-04-18

4.  Chlamydia psittaci in ocular adnexa MALT lymphoma: a possible role in lymphomagenesis and a different geographical distribution.

Authors:  Francesca Collina; Anna De Chiara; Amalia De Renzo; Gaetano De Rosa; Gerardo Botti; Renato Franco
Journal:  Infect Agent Cancer       Date:  2012-04-02       Impact factor: 2.965

5.  Immunoglobulin G4-related disease (IgG4-RD) in the orbit: mucosa-associated lymphoid tissue (MALT)-type lymphomas.

Authors:  Krzysztof Oleś; Jacek Składzień; Wojciech Szczepański; Krzysztof Okoń; Joanna Leszczyńska; Emilia Bojanowska; Krzysztof Bartuś; Joanna Mika
Journal:  Med Sci Monit       Date:  2015-04-10

6.  Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies.

Authors:  Andi K Cani; Moaaz Soliman; Daniel H Hovelson; Chia-Jen Liu; Andrew S McDaniel; Michaela J Haller; Jarred V Bratley; Samantha E Rahrig; Qiang Li; César A Briceño; Scott A Tomlins; Rajesh C Rao
Journal:  Mod Pathol       Date:  2016-04-22       Impact factor: 7.842

7.  Modern techniques of magnetic resonance in the evaluation of primary central nervous system lymphoma: contributions to the diagnosis and differential diagnosis.

Authors:  Antonio José da Rocha; Bruno Vasconcelos Sobreira Guedes; Talita Maira Bueno da Silveira da Rocha; Antonio Carlos Martins Maia Junior; Carlos Sérgio Chiattone
Journal:  Rev Bras Hematol Hemoter       Date:  2015-12-31

8.  Genome-wide DNA methylation profiles according to Chlamydophila psittaci infection and the response to doxycycline treatment in ocular adnexal lymphoma.

Authors:  Min Joung Lee; Byung-Joo Min; Ho-Kyung Choung; Namju Kim; Young A Kim; Sang In Khwarg
Journal:  Mol Vis       Date:  2014-07-19       Impact factor: 2.367

9.  Monthly administration of rituximab is useful for patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma.

Authors:  T Mino; K Mihara; T Yoshida; Y Takihara; T Ichinohe
Journal:  Blood Cancer J       Date:  2014-09-12       Impact factor: 11.037

10.  Recurrent mutations in NF-κB pathway components, KMT2D, and NOTCH1/2 in ocular adnexal MALT-type marginal zone lymphomas.

Authors:  Patricia Johansson; Ludger Klein-Hitpass; Florian Grabellus; Georg Arnold; Wolfram Klapper; Roman Pförtner; Ulrich Dührsen; Anja Eckstein; Jan Dürig; Ralf Küppers
Journal:  Oncotarget       Date:  2016-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.